CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

13 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

30 Jun 2023 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

13 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

07 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 16:01:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

04 May 2023 09:00:01 By Nasdaq GlobeNewswire

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

27 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

23 Mar 2023 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

08 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award

02 Mar 2023 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan

16 Feb 2023 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

25 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

19 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform

12 Jan 2023 09:26:27 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

10 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10

03 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022

06 Oct 2022 09:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

07 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

10 Aug 2022 16:05:00 By Nasdaq GlobeNewswire